Illumina and Janssen Collaborate to Advance MRD Cancer Test
This collaboration relates to the development of Illumina’s MRD assay, a solution that detects ctDNA to understand the persistence of disease.
Read MorePosted by Andy Lundin | Jan 5, 2024 | Molecular Diagnostics |
This collaboration relates to the development of Illumina’s MRD assay, a solution that detects ctDNA to understand the persistence of disease.
Read MorePosted by Andy Lundin | Jan 5, 2024 | Womens Health |
Researchers created a new screening test that uses a blood sample from an expectant mother to scrutinize all the genes in the fetus.
Read MorePosted by Andy Lundin | Jan 4, 2024 | Diagnostic Technologies |
The new biorepository can be instrumental in genetic and biomarker identification for patient populations with rapid disease progression.
Read MorePosted by Andy Lundin | Jan 3, 2024 | Melanoma |
The combined biomarkers, AMBRA1 and loricrin can be used to reliably stratify stage I and II melanomas at genuine low risk of progression.
Read MorePosted by Andy Lundin | Jan 3, 2024 | Covid 19 |
This research aims to improve the understanding of how maternal antibodies against SARS-CoV-2 are transferred to and persist in newborns.
Read More